FilingReader Intelligence

Alembic Pharmaceuticals receives USFDA clearance for Karakhadi facility

June 27, 2025 at 09:33 AM UTCBy FilingReader AI

Alembic Pharmaceuticals (BSE: 533573) announced today that it has received an Establishment Inspection Report (EIR) from the USFDA for its API-III manufacturing facility located in Karakhadi, India. The inspection by the USFDA took place between March 17, 2025, and March 21, 2025. The company has informed the National Stock Exchange of India Ltd about this development. This approval signifies the successful completion of the USFDA inspection and allows the company to continue manufacturing and exporting pharmaceutical products from this facility to the United States.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when ALEMBIC PHARMACEUTICALS publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →